AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21346067 — intervention group
Group type: EXPERIMENTAL
Intervention: MRrhTSH 0.01 mg (group B, n = 30)
Number of subjects: 95
Study 21346067 — intervention group
Group type: EXPERIMENTAL
Intervention: MRrhTSH 0.03 mg (group C, n = 33)
Number of subjects: 95
Study 18678569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic electrical stimulation
Number of subjects: 22
Study 18678569 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-triggered electrical stimulation
Number of subjects: 22
Study 16339498 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA isomeric mixture
Number of subjects: 40
Study 16339498 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 40
Study 14636819 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 18 mg/70 kg intramuscular
Number of subjects: 4
Study 14636819 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 10 mg/70 kg intravenous
Number of subjects: 4
Study 14636819 — intervention group
Group type: EXPERIMENTAL
Intervention: hydromorphone 2 mg/70 kg intravenous
Number of subjects: 4
Study 14636819 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4
Study 11002953 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg misoprostol given orally
Number of subjects: 1000
Study 11002953 — intervention group
Group type: COMPARATOR
Intervention: Standard oxytocic regimens (oxytocin, oxytocin with ergometrine, or ergometrine)
Number of subjects: 1000
Study 8840306 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/day oral calcitriol (calcitriol group, n = 8)
Number of subjects: 26
Study 8840306 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day calcium carbonate (CaCO3 group, n = 10)
Number of subjects: 26
Study 8840306 — intervention group
Group type: COMPARATOR
Intervention: Neither (control uraemic group, n = 8)
Number of subjects: 26
Study 1729619 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1 percent tretinoin
Number of subjects: 58
Study 1729619 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 58
Study 3885699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil (1.5 mg/kg intravenous bolus followed by 50 micrograms/kg/min infusion for 3 hours)
Number of subjects: 11
Study 3885699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3885699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil
Number of subjects: 11
Study 29973280 — intervention group
Group type: EXPERIMENTAL
Intervention: IAU+P4P
Number of subjects: 1173
Study 29973280 — intervention group
Group type: COMPARATOR
Intervention: IAU
Number of subjects: 1173
Study 27175664 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid group (fentanyl via IV PCA)
Number of subjects: 60
Study 27175664 — intervention group
Group type: COMPARATOR
Intervention: ON-Q group (continuous wound infiltration of 0.5% ropivacaine with ON-Q pump and tramadol via IV PCA)
Number of subjects: 60
Study 27366404 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 82
Study 27366404 — intervention group
Group type: COMPARATOR
Intervention: Control group (haemodynamic parameters)
Number of subjects: 82
Study 22541165 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-back test for 30 min
Number of subjects: 12
Study 22541165 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-back test for 30 min
Number of subjects: 12
Study 20018492 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin (16g/day)
Number of subjects: 16
Study 20018492 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus dosing of piperacillin (4g every 6h)
Number of subjects: 16
Study 18569677 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 2 group
Number of subjects: 0
Study 18569677 — intervention group
Group type: COMPARATOR
Intervention: Age 10 group
Number of subjects: 0
Study 18569677 — intervention group
Group type: EXPERIMENTAL
Intervention: False event recall
Number of subjects: 0
Study 16622039 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/h GTN for 1 week (n=17)
Number of subjects: 28
Study 16622039 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 nM, 300 nM, or 1 microM GTN during ex vivo expansion (n=10)
Number of subjects: 28
Study 16622039 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n=11)
Number of subjects: 28
Study 16622039 — intervention group
Group type: COMPARATOR
Intervention: EPCs expanded without GTN (n=10)
Number of subjects: 28
Study 12533579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragment-Fissure herniations (89 patients)
Number of subjects: 187
Study 12533579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragment-Contained herniations (42 patients)
Number of subjects: 187
Study 12533579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragment-Defect herniations (33 patients)
Number of subjects: 187
Study 12533579 — intervention group
Group type: EXPERIMENTAL
Intervention: No Fragment-Contained herniations (16 patients)
Number of subjects: 187
Study 11011494 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver
Number of subjects: 0
Study 11011494 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 8970420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Number of subjects: 119
Study 8970420 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 119
Study 1461145 — intervention group
Group type: EXPERIMENTAL
Intervention: high-MUFA/low-CHO diet
Number of subjects: 10
Study 1461145 — intervention group
Group type: COMPARATOR
Intervention: low-MUFA/high-CHO diet
Number of subjects: 10
Study 6539224 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg codeine phosphate
Number of subjects: 8
Study 6539224 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg dextromethorphan hydrobromide
Number of subjects: 8
Study 6539224 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg codeine phosphate
Number of subjects: 8
Study 6539224 — intervention group
Group type: COMPARATOR
Intervention: 30 mg dextromethorphan hydrobromide
Number of subjects: 8
Study 6539224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 28930881 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Motion Release (TMR)
Number of subjects: 20
Study 28930881 — intervention group
Group type: COMPARATOR
Intervention: Dynamic warm-up (TWG)
Number of subjects: 20
Study 28930881 — intervention group
Group type: COMPARATOR
Intervention: Dynamic warm-up after TMR
Number of subjects: 20
Study 28930881 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR after dynamic warm-up
Number of subjects: 20
Study 30694205 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention (ikherstel)
Number of subjects: 151
Study 29061224 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase-4 (DPP-4) activity
Number of subjects: 125
Study 29061224 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1 (GLP-1) total activity
Number of subjects: 125
Study 25214068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pushable coil
Number of subjects: 50
Study 25214068 — intervention group
Group type: COMPARATOR
Intervention: Detachable coil
Number of subjects: 50
Study 23475835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation
Number of subjects: 0
Study 23475835 — intervention group
Group type: COMPARATOR
Intervention: Contact lens (CL) treatment
Number of subjects: 0
Study 21519726 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized weight loss diet (30% energy restriction) with macronutrient distribution of 40/30/30, high meal frequency (7/day), low glycemic index/load, high antioxidant capacity, and adherence to the Mediterranean diet.
Number of subjects: 100
Study 21519726 — intervention group
Group type: COMPARATOR
Intervention: Control group diet with the same energy restriction based on the American Heart Association pattern.
Number of subjects: 100
Study 18972725 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-combination needling method (acupuncture, acupoint-injection, fire-needle therapy)
Number of subjects: 86
Study 18972725 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture and acupoint-injection (control group)
Number of subjects: 86
Study 16939373 — intervention group
Group type: EXPERIMENTAL
Intervention: Microtapered needle (TN3305, 'Needle T')
Number of subjects: 99
Study 16939373 — intervention group
Group type: COMPARATOR
Intervention: Standard thin wall needle (Micro‐Fine +, 31 gauge, 5 mm, 'Needle B')
Number of subjects: 99
Study 16939373 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both needles
Number of subjects: 99
Study 16939373 — intervention group
Group type: COMPARATOR
Intervention: Both needles
Number of subjects: 99
Study 12642637 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate)
Number of subjects: 16608
Study 12642637 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 16608
Study 12642637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 10713746 — intervention group
Group type: EXPERIMENTAL
Intervention: Borage oil supplementation (230 or 460 mg gamma‐linolenic acid per day for one week)
Number of subjects: 40
Study 10713746 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic mothers (no supplementation)
Number of subjects: 40
Study 10713746 — intervention group
Group type: COMPARATOR
Intervention: Non‐atopic mothers (control)
Number of subjects: 40
Study 8884934 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.91 MJ)
Number of subjects: 20
Study 8884934 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO, 0.72 MJ)
Number of subjects: 20
Study 8884934 — intervention group
Group type: COMPARATOR
Intervention: No alcohol
Number of subjects: 20
Study 8884934 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 20
Study 1314965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (1500 a PPT-Units/d Mono-Embolex NM)
Number of subjects: 200
Study 1314965 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU t.i.d.)
Number of subjects: 200
Study 6546602 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP
Number of subjects: 73
Study 6546602 — intervention group
Group type: COMPARATOR
Intervention: OPP
Number of subjects: 73
Study 29534940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 2454
Study 29534940 — intervention group
Group type: COMPARATOR
Intervention: RECORD-1 and AXIS trials
Number of subjects: 2454
Study 29534940 — intervention group
Group type: COMPARATOR
Intervention: INTORSECT trial
Number of subjects: 2454
Study 27129362 — intervention group
Group type: EXPERIMENTAL
Intervention: DR-HC 5mg
Number of subjects: 31
Study 27129362 — intervention group
Group type: EXPERIMENTAL
Intervention: DR-HC 20mg
Number of subjects: 31
Study 27129362 — intervention group
Group type: EXPERIMENTAL
Intervention: DR-HC 15mg (3×5)
Number of subjects: 31
Study 25604767 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention including modified insecticide application, education regarding Chagas disease and risk factors, and participatory rodent control.
Number of subjects: 0
Study 25604767 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 0
Study 23913972 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil (a progesterone receptor modulator)
Number of subjects: 0
Study 23913972 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20367810 — intervention group
Group type: EXPERIMENTAL
Intervention: Education session on SMART Goal Evaluation Method and 3 months of follow-up support (n = 60)
Number of subjects: 120
Study 20367810 — intervention group
Group type: COMPARATOR
Intervention: Control group attended a workshop on evidence-based practice (n = 60)
Number of subjects: 120
Study 18926878 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the left temporal cortex (with cathodal stimulation of the right temporal cortex)
Number of subjects: 14
Study 18926878 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 14
Study 17035531 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 22
Study 17035531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12412691 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound (EBUS) guided TBBX
Number of subjects: 50
Study 12412691 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided TBBX
Number of subjects: 50
Study 10101617 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV intervention
Number of subjects: 3357
Study 10101617 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV seropositive status
Number of subjects: 3357
Study 10101617 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS information received prior to intervention
Number of subjects: 3357
Study 10101617 — intervention group
Group type: EXPERIMENTAL
Intervention: Having multiple sex partners
Number of subjects: 3357
Study 10101617 — intervention group
Group type: EXPERIMENTAL
Intervention: Being single with multiple sex partners
Number of subjects: 3357
Study 10101617 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchanging drugs or money for sex
Number of subjects: 3357
Study 7485711 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (4 mg/kg/day for three days with mefloquine 25 mg/kg on the second day)
Number of subjects: 60
Study 7485711 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine (20 mg of salt/kg initially then 10 mg/kg every 8 hr, followed by mefloquine 25 mg/kg)
Number of subjects: 60
Study 1775483 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste and AmF/SnF2 mouthwash
Number of subjects: 44
Study 1775483 — intervention group
Group type: COMPARATOR
Intervention: NaF toothpaste and NaF mouthwash
Number of subjects: 44
Study 6821197 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate eye drops
Number of subjects: 0
Study 6821197 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% sodium cromoglycate eye drops
Number of subjects: 0
Study 31028737 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration of 4% articaine 1.8 mL
Number of subjects: 72
Study 31028737 — intervention group
Group type: COMPARATOR
Intervention: Buccal infiltration of 4% articaine 1.8 mL plus lingual injection of normal saline 0.4 mL
Number of subjects: 72
Study 28408335 — intervention group
Group type: EXPERIMENTAL
Intervention: PCST-Full (5 sessions)
Number of subjects: 327
Study 28408335 — intervention group
Group type: EXPERIMENTAL
Intervention: PCST-Brief (1 session of 60 minutes)
Number of subjects: 327
Study 28408335 — intervention group
Group type: COMPARATOR
Intervention: Additional PCST sessions, maintenance calls, or no further intervention (based on intervention response)
Number of subjects: 327
Study 27164977 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperextension maneuver during autograft fixation on the tibial side
Number of subjects: 100
Study 27164977 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hyperextension maneuver)
Number of subjects: 100
Study 24099546 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting-on from current number on the board while playing a 0-100 number board game
Number of subjects: 0
Study 24099546 — intervention group
Group type: COMPARATOR
Intervention: Standard count-from-1 procedure while playing the same game
Number of subjects: 0
Study 24099546 — intervention group
Group type: COMPARATOR
Intervention: Practice encoding the numerals 1-100 outside of the context of a number board game
Number of subjects: 0
Study 22018594 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg somatuline® (lanreotide) administered by a single subcutaneous injection for 2 weeks (Group B)
Number of subjects: 130
Study 22018594 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 190 mg/m2 + carboplatin AUC=5.5 for up to 6 cycles (Group A, control group)
Number of subjects: 130
Study 22018594 — intervention group
Group type: COMPARATOR
Intervention: 60 mg somatuline® autogel for 4 weeks (Group C)
Number of subjects: 130
Study 19073237 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive participants
Number of subjects: 0
Study 19073237 — intervention group
Group type: COMPARATOR
Intervention: Non-depressive participants
Number of subjects: 0
Study 17428109 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (subcutaneous, twice daily)
Number of subjects: 0
Study 17428109 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0
Study 15522938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (30-50 mg twice daily)
Number of subjects: 78
Study 15522938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 78
Study 15522938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 12228208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus chlorambucil
Number of subjects: 544
Study 12228208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 544
Study 12228208 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 544
Study 10093649 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB
Number of subjects: 42
Study 10093649 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam (Control)
Number of subjects: 42
Study 7486180 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (0.1 mg/kg)
Number of subjects: 102
Study 7486180 — intervention group
Group type: COMPARATOR
Intervention: placebo (normal saline)
Number of subjects: 102
Study 7486180 — intervention group
Group type: COMPARATOR
Intervention: droperidol (75 micrograms/kg)
Number of subjects: 102
Study 7486180 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 102
Study 2403058 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (Ex) group walking at 60% heart‐rate reserve (134 +/- 2 bpm) for 45-min sessions, five times per week
Number of subjects: 21
Study 2403058 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise (Nex) group
Number of subjects: 21
Study 2403058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Ex and Nex groups
Number of subjects: 21
Study 7358847 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (4 weeks)
Number of subjects: 17
Study 7358847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31106492 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitioning to very low nicotine content cigarettes plus nicotine patch
Number of subjects: 68
Study 31106492 — intervention group
Group type: COMPARATOR
Intervention: Reducing daily cigarette consumption plus nicotine patch
Number of subjects: 68
Study 28402516 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery plus recombinant Tissue plasminogen activator (rtPA)
Number of subjects: 123
Study 26289560 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi feedback methods (three different methods)
Number of subjects: 0
Study 26289560 — intervention group
Group type: EXPERIMENTAL
Intervention: Core outcome set
Number of subjects: 0
Study 26289560 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus meeting
Number of subjects: 0
Study 23011257 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT (Gynecare(®))
Number of subjects: 71
Study 23011257 — intervention group
Group type: COMPARATOR
Intervention: TOT (Aris(®))
Number of subjects: 71
Study 21419770 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2b (0.5 μg/kg/week)
Number of subjects: 626
Study 21419770 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 626
Study 19046169 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus-containing vaginal tablets
Number of subjects: 39
Study 19046169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17429915 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (250 IU/kg three times weekly, total of 15 times starting on day of life 5)
Number of subjects: 31
Study 12671188 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 26
Study 12671188 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 26
Study 10867388 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic strategy
Number of subjects: 0
Study 10867388 — intervention group
Group type: COMPARATOR
Intervention: Clinical tests
Number of subjects: 0
Study 10867388 — intervention group
Group type: EXPERIMENTAL
Intervention: Integral valuation of treatment
Number of subjects: 0
Study 8772901 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation to both mother and infant (300,000 IU for mothers and 200,000 IU for infants)
Number of subjects: 909
Study 8772901 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A supplementation to mother and placebo to infant
Number of subjects: 909
Study 8772901 — intervention group
Group type: COMPARATOR
Intervention: Placebo to both mother and infant
Number of subjects: 909
Study 1308804 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol
Number of subjects: 0
Study 1308804 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anesthesia with halothane
Number of subjects: 0
Study 6442856 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-elemental diet (SED) with an osmolarity of 302 milliosmol per liter, low lactose content, and high lactalbumin hydrolysate (1 g/100 ml)
Number of subjects: 38
Study 6442856 — intervention group
Group type: COMPARATOR
Intervention: Available proprietary formulas or diluted cow's milk with added carbohydrates
Number of subjects: 38
Study 3717617 — intervention group
Group type: EXPERIMENTAL
Intervention: Rüsch tube with low residual volume cuff, inflated to minimum occluding volume
Number of subjects: 47
Study 3717617 — intervention group
Group type: EXPERIMENTAL
Intervention: Mallinckrodt Hi‐Lo tube with high residual volume cuff, inflated to 29‐31 cm H2O
Number of subjects: 47
Study 3717617 — intervention group
Group type: EXPERIMENTAL
Intervention: NL tube with high residual volume cuff and automatic cuff pressure regulation, inflated to 29‐31 cm H2O
Number of subjects: 47
Study 29564932 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐200 lispro
Number of subjects: 126